Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus a randomized, multicenter, 24-month study

Tytuł :
Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus a randomized, multicenter, 24-month study
Index Terms :
Adult
Calcineurin - antagonists & inhibitors
Sirolimus - administration & dosage, adverse effects, analogs & derivatives
TOR Serine-Threonine Kinases - antagonists & inhibitors
Time Factors
Treatment Outcome
Creatinine - blood, urine
Female
Glomerular Filtration Rate - drug effects
Humans
Immunosuppressive Agents - administration & dosage, adverse effects
Kidney Transplantation - immunology, physiology
Male
Middle Aged
info:eu-repo/semantics/article
Wydawca :
Lippincott Williams & Wilkins 2011
Dodane szczegóły :
UCL - SSS/IREC/NEFR - Pôle de Néphrologie
UCL - (SLuc) Service de néphrologie
Holdaas, Hallvard
Rostaing, Lionel
Serón, Daniel
Cole, Edward
Chapman, Jeremy
Fellstrøm, Bengt
Strom, Erik H
Jardine, Alan
Midtvedt, Karsten
Machein, Uwe
Ulbricht, Bettina
Karpov, Alexander
O'Connell, Philip J
ASCERTAIN Investigators
Goffin, Eric
Typ dokumentu :
Zasób elektroniczny
URL :
http://hdl.handle.net/2078.1/113284
Dostępność :
Open access content. Open access content
info:eu-repo/semantics/closedAccess
Pozostałe numery :
UCDLC oai:dial.uclouvain.be:boreal:113284
boreal:113284
info:doi/10.1097/TP.0b013e318224c12d
info:pmid/21697773
urn:ISSN:0041-1337
urn:EISSN:1534-6080
1130512248
Źródło wspomagające :
UNIVERSITE CATHOLIQUE DE LOUVAIN
From OAIster®, provided by the OCLC Cooperative.
Numer akcesji :
edsoai.on1130512248
Zasób elektroniczny
BACKGROUND: Benefits of conversion from calcineurin inhibitor (CNI) to mammalian target of rapamycin inhibitor-based immunosuppression in long-term kidney transplant patients remain uncertain. METHODS: ASCERTAIN was a 24-month, open-label, multicenter study. Kidney transplant patients more than 6 months posttransplant receiving CNI (baseline glomerular filtration rate [GFR] 30-70 mL/min/1.73 m) were randomized to everolimus with CNI elimination (n=127) or CNI minimization (n=144), or continued CNI unchanged (controls, n=123) to assess the effect on measured GFR at month 24 after randomization. RESULTS: Renal function was stable in all groups to month 24. Mean measured GFR at month 24, the primary endpoint, was 48.0±22.0 mL/min/1.73 m, 46.6±21.1 mL/min/1.73 m, and 46.0±20.4 mL/min/1.73 m in the CNI elimination, CNI minimization, and control groups, respectively. Differences between CNI elimination (1.12 mL/min/1.73 m, 95% confidence interval [CI] -3.51 to 5.76, P=0.63) and CNI minimization (0.59 mL/min/1.73 m, 95% CI -3.88 to 5.07, P=0.79) versus controls at month 24 were nonsignificant that is, the primary endpoint was not met. No efficacy endpoint differed significantly between groups. Post hoc analyses showed that patients with baseline creatinine clearance (CrCl) more than 50 mL/min had a significantly greater increase in measured GFR after CNI elimination versus controls (difference 11.4 mL/min/1.73 m, 95% CI 2.1 to 20.8 mL/min/1.73 m, P=0.017). Adverse events resulted in discontinuation in 36 (28.3%) CNI elimination patients, 24 (16.7%) CNI minimization patients, and 5 (4.1%) controls (P<0.001 vs. CNI elimination; P=0.020 vs. CNI minimization). CONCLUSION: Conversion to everolimus with CNI elimination or minimization a mean of 5.6 years after kidney transplantation had no overall renal benefit and was associated with more frequent adverse events and discontinuations. Patients with CrCl more than 50 mL/min may benefit from a change in therapy more than 6 months

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies